Business Context and Reporting Period
This Form 8-K Current Report was filed by Cocrystal Pharma, Inc. on February 6, 2018, covering events occurring on January 31, 2018. The filing primarily addresses unregistered sales of equity securities in the form of a debt instrument.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial event reported is as follows:
- Debt Financing: The Company borrowed $1,000,000 from OPKO Health, Inc.
- Instrument: 8% Convertible Note due January 31, 2020.
- Conversion Price: $8.10 per share (subject to adjustment).
- Liquidity Impact: Immediate cash inflow of $1,000,000.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement (SPA) and the issuance of the Convertible Note. The filing notes that these terms are identical to those disclosed in a prior Form 8-K filed on December 1, 2017, adjusted for a 1-for-30 reverse stock split that occurred on January 18, 2018.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. Key terms and contingencies regarding the Note include:
- Automatic Conversion: The Note automatically converts upon a "Financing" (defined as raising at least $10,000,000 in gross proceeds) or a change of control/sale of substantially all assets.
- Conversion Price Adjustment: Upon a Financing, the conversion price becomes the lesser of $8.10 or the price per share of the new securities sold.
- Regulatory Status: The Note was issued under Section 4(a)(2) and Rule 506 exemptions. It cannot be resold in the U.S. without an effective registration statement or exemption.
Investor Verification Checklist
- Verify the impact of the 1-for-30 reverse stock split on the $8.10 conversion price relative to current market trading.
- Confirm the Company's current cash runway and whether the $1,000,000 proceeds are sufficient to reach the $10,000,000 financing threshold required for automatic conversion.
- Review the December 1, 2017 Form 8-K for the full text of the Securities Purchase Agreement and Note terms incorporated by reference.
- Assess the dilution potential if a future financing triggers the automatic conversion at a price lower than $8.10.